Skip to main content

Advertisement

Log in

Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Splanchnic vein thrombosis (SVT) is an uncommon form of venous thrombosis. Management can be challenging due to underlying conditions, increased bleeding risk, and lack of evidence from clinical trials. We sought to characterize the presentation and management of patients with SVT at a large tertiary hospital. A total of 43 patients’ electronic medical records were reviewed. Median age at diagnosis was 43 (18–71). Sixteen patients had isolated portal vein thrombosis (37.2 %), and 16 (37.2 %) had thrombosis involving multiple splanchnic veins. Abdominal pain was the most common clinical presentation (67.4 %). Thrombophilia was present in 18 patients (41.9 %), nine had underlying liver disease (20.9 %) and seven had inflammatory bowel disease (16.3 %). Thirty-nine (90.7 %) patients were treated with anticoagulation, and 11(25.6 %) of these patients underwent interventional procedures. Thirty (69.8 %) patients remained on indefinite anticoagulation. Results of follow-up imaging at least 1 month after diagnosis were available for 29 patients; imaging showed chronic, stable thrombosis in 14 patients (48.3 %), resolution of thrombosis in 13 patients (44.8 %) and asymptomatic progression in two patients (6.9 %). Recurrent thrombosis occurred in four patients (9.3 %). Major bleeding occurred in eight patients who received anticoagulation (18.6 %), including fatal subdural hematoma in one patient. In this cohort of patients managed by hematologists and gastroenterologists, the majority of patients were treated with anticoagulation. Interventional procedures were higher than in previously reported series. Our study strongly supports the interdisciplinary management of splanchnic venous thrombosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Explore related subjects

Discover the latest articles, news and stories from top researchers in related subjects.

References

  1. Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH (2006) Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 12:2115–2119

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ageno W, Riva N, Schulman S et al (2014) Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. Semin Thromb Hemost 40:99–105

    PubMed  Google Scholar 

  3. Riva N, Donadini MP, Dentali F, Squizzato A, Ageno W (2012) Clinical approach to splanchnic vein thrombosis: risk factors and treatment. Thromb Res 130(Suppl 1):S1–S3

    Article  PubMed  Google Scholar 

  4. Amitrano L, Guardascione MA, Scaglione M et al (2012) Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis. Eur J Gastroenterol Hepatol 24:1381–1385

    Article  CAS  PubMed  Google Scholar 

  5. Yonal I, Pinarbasi B, Hindilerden F et al (2012) The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis. J Thromb Thrombolysis 34:388–396

    Article  CAS  PubMed  Google Scholar 

  6. Sekhar M, McVinnie K, Burroughs AK (2013) Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol 162:730–747

    Article  CAS  PubMed  Google Scholar 

  7. Hoekstra J, Leebeek FW, Plessier A et al (2009) Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol 51:696–706

    Article  CAS  PubMed  Google Scholar 

  8. Mutreja D, Kotru M, Sazawal S et al (2015) Hereditary and acquired thrombophilia in splanchnic vein thrombosis: a single-center experience. Clin Appl Thromb Hemost 21:521–526

    Article  CAS  PubMed  Google Scholar 

  9. Bianchini M, De Pietri L, Villa E (2014) Coagulopathy in liver diseases: complication or therapy? Dig Dis 32:609–614

    Article  PubMed  Google Scholar 

  10. Tait C, Baglin T, Watson H et al (2012) Guidelines on the investigation and management of venous thrombosis at unusual sites. Br J Haematol 159:28–38

    Article  PubMed  Google Scholar 

  11. Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW (2012) Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120:4921–4928

    Article  CAS  PubMed  Google Scholar 

  12. Colaizzo D, Amitrano L, Guardascione MA et al (2013) Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation. Thromb Res 132:e99–e104

    Article  CAS  PubMed  Google Scholar 

  13. Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S–e494S

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kearon C, Akl EA, Ornellas J et al. (2016) Antithrombotic Therapy for VTE disease. Chest Guideline. Chest. doi:10.1016/j.chest.2015.11.026

  15. Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694

    Article  CAS  PubMed  Google Scholar 

  16. Martinez M, Tandra A, Vuppalanchi R (2014) Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatol 60:425–426

    Article  CAS  Google Scholar 

  17. Lenz K, Dieplinger B, Buder R, Piringer P, Rauch M, Voglmayr M (2014) Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban. Z Gastroenterol 52:1175–1177

    Article  CAS  PubMed  Google Scholar 

  18. Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373:2413–2424

    Article  CAS  PubMed  Google Scholar 

  19. Pollack CV Jr, Reilly PA, Eikelboom J et al (2015) Idarucizumab for Dabigatran Reversal. N Engl J Med 373:511–520

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr. Stephen M. Pastores for his valuable suggestions to the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Maria T. DeSancho.

Ethics declarations

Conflicts of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klute, K., DeFilippis, E.M., Shillingford, K. et al. Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience. J Thromb Thrombolysis 42, 267–271 (2016). https://doi.org/10.1007/s11239-016-1337-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-016-1337-4

Keywords

Navigation